Samsung Biologics Co Ltd (207940) — Cash Flow Quality Index
Samsung Biologics Co Ltd (207940) has a Cash Flow Quality Index of 1.25x as of September 2025. Operating cash flow of ₩619.30 Billion exceeds net income of ₩496.48 Billion, indicating high earnings quality where cash backs reported profits. Explore cash flow conversion of Samsung Biologics Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Samsung Biologics Co Ltd Cash Flow Quality Index (2015–2024)
Historical Cash Flow Quality Index for Samsung Biologics Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 207940 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Samsung Biologics Co Ltd (2015–2024)
Year-by-year earnings quality comparison for Samsung Biologics Co Ltd. For live market cap and the full company financial profile, see 207940 stock market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.58x | ₩1.66 Trillion | ₩1.05 Trillion | ▼ -18.7% |
| 2023 | 1.94x | ₩1.67 Trillion | ₩857.69 Billion | ▲ +40.0% |
| 2022 | 1.39x | ₩953.05 Billion | ₩686.79 Billion | ▲ +20.1% |
| 2021 | 1.16x | ₩454.60 Billion | ₩393.59 Billion | ▲ +37.7% |
| 2020 | 0.84x | ₩202.09 Billion | ₩240.97 Billion | ▲ +1575.9% |
| 2019 | 0.05x | ₩10.15 Billion | ₩202.90 Billion | ▲ +134.0% |
| 2018 | -0.15x | ₩-33.02 Billion | ₩224.11 Billion | ▼ -6.5% |
| 2015 | -0.14x | ₩-265.51 Billion | ₩1.92 Trillion | — |